Table 1.
Main characteristics of eligible studies.
| Author (yrs) | Cases | Age (mean yrs) |
HG I/II (III/IV) | Metastatic disease | Treatment | PCR exons | Deaths in 2 years, N (%) | Chemotherapy response (criteria) |
|---|---|---|---|---|---|---|---|---|
| Yokoyama et al. (1998) [23] | 17 | 15 | (8/7) | 2 | NC + surgery | 4–8 | 1 (6) | 6/14 (S-K) |
| Radig et al. (1998) [24] | 18 | 34 | 10/8 | 0 | Surgery | 4–8 | 2 (17) | NR |
| Goto et al. (1998) [12] | 32 | 16 | (23/9) | 8 | NC + surgery | MS | 14 (44) | 3/31 (N90) |
| Tsuchiya et al. (2000) [13] | 27 | 15 | NR | 2 | NC + surgery | 5–9 | 11 (41) | NR |
| Kawaguchi et al. (2002) [25] | 23 | 55 | (8/15) | NR | Surgery | 5–9 | 12 (52) | NR |
| Patiño-García et al. (2003) [26] | 41 | 14 | NR | 8 | NR | 5–8 | 7 (18) | 22/41 (N90) |
| Entz-Werle et al. (2003) [27] | 54 | 13 | (43/11) | 6 | NC + surgery | MS | 4 (7) | 30/53 (Huvos) |
| Richter et al. (2013) [28] | 17 | 34 | NR | NR | Surgery | 5–9 | 5 (31) | 3/17 (Huvos) |
Note. Exons: exons of the TP53 gene analyzed by polymerase chain reaction.
N: number; yrs: years; HG: histological grades; NC: neoadjuvant chemotherapy; Huvos: histological response based on the Huvos grading system; NR: not reported; N90: histological response based on >90% tumor cell necrosis; PCR: polymerase chain reaction; S-K: histological response based on Salzer-Kuntschik's classification; MS: microsatellite primers.